Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 20/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6217023 | 0.99 | CCR3 (0.62) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7972807 | 0.86 | CCR3 (0.60) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6337473 | 0.83 | CCR3 (0.43) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL6217021 | 0.77 | MGLL (0.40) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6215640 | 0.77 | CCR3 (1.00) | CCR3HTR2A | |
| SCHEMBL6337783 | 0.77 | CCR3 (1.00) | CCR3HTR2A | |
| SCHEMBL6780545 | 0.75 | CCR3 (1.00) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6780550 | 0.75 | CCR3 (1.00) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7656814 | 0.75 | CCR3 (1.00) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7656820 | 0.75 | CCR3 (1.00) | CCR3HTR2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780857-B2 | FOR TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES SUCH AS ASTHMA AND ALLERGIC DISEASES, AS WELL AS AUTOIMMUNE PATHOLOGIES SUCH AS RHEUMATOID ARTHRITIS AND ATHEROSCLEROSIS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006107-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, CCR10 | CCR3 1/4885HTR2A 1608/4885SLC6A2 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.